American Journal of Cardiology
Volume 104, Issue 6 , Pages 829-834, 15 September 2009

Effects of Increasing High-Density Lipoprotein Cholesterol and Decreasing Low-Density Lipoprotein Cholesterol on the Incidence of First Acute Coronary Events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study)

  • Yadong Cui, MD, PhD

      Affiliations

    • Merck & Compnay, Incorported, Whitehouse Station, New Jersey
    • ,
  • Douglas J. Watson, PhD

      Affiliations

    • Merck & Compnay, Incorported, Whitehouse Station, New Jersey
    • ,
  • Cynthia J. Girman, DrPH

      Affiliations

    • Merck & Compnay, Incorported, Whitehouse Station, New Jersey
    • ,
  • Deborah R. Shapiro, DrPH

      Affiliations

    • Merck & Compnay, Incorported, Whitehouse Station, New Jersey
    • ,
  • Antonio M. Gotto, MD, DPhil

      Affiliations

    • Cornell University Weill Medical College, New York, New York
    • ,
  • Patricia Hiserote, DO

      Affiliations

    • Touro University, Vallejo, California
    • ,
  • Michael B. Clearfield, DO

      Affiliations

    • Touro University, Vallejo, California
    • Corresponding Author InformationCorresponding author: Tel: (707) 638-5982; fax: (707) 638-5924

Received 18 February 2009; received in revised form 2 May 2009; accepted 2 May 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study and its report were supported by Merck & Co., Inc., North Wales, Pennsylvania.

 Drs. Cui, Watson, Girman, and Shapiro are employees and shareholders of Merck & Co., Inc., North Wales, Pennsylvania. Dr. Gotto is a consultant for Genentech (South San Francisco, California), Kowa (Nagoya, Japan), Merck (Whitehouse Station, New Jersey) and Merck/Schering-Plough (Kenilworth, New Jersey), is on the board of directors of Aegerion (Bridgewater, New Jersey) and Arisaph Pharmaceuticals (Boston, Massachusetts), and is a member of the advisory boards for DuPont (Wilmington, Delaware) and Novartis (Cambridge, Massachusetts). Dr. Clearfield is a consultant and speaker for AstraZeneca (Wilmington, Delaware) and Merck & Co., Inc. (North Wales, Pennsylvania).

PII: S0002-9149(09)01054-6

doi:10.1016/j.amjcard.2009.05.020

American Journal of Cardiology
Volume 104, Issue 6 , Pages 829-834, 15 September 2009

Article Tools

* Image Usage & Resolution